JD Supra

Federal Court upholds validity of patent relating to paliperidone palmitate

On August 23, 2022, the Federal Court issued its public judgment and reasons in two actions under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations (the “Regulations”) ...
News Medical

Invega Hafyera

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. INVEGA HAFYERA contains the active ingredient paliperidone palmitate.
JD Supra

Federal Court of Appeal affirms paliperidone palmitate claims are not unpatentable methods of medical treatment

In a 2022 decision involving Janssen and Pharmascience, the Federal Court found that the claims of Canadian Patent No. 2,655,335 (335 patent, relating to paliperidone palmitate (Janssen’s INVEGA ...
Medscape

Onset of Efficacy and Tolerability Following the Initiation Dosing of Long-acting Paliperidone Palmitate

With respect to tolerability concerns with the recommended paliperidone palmitate initiation dosing, this study did not reveal unexpected adverse events or high rates of specific adverse events in the ...